Windward Bio Group AG Achieves Remarkable Nasdaq Debut with 68% Share Surge

Windward Bio Group AG: A Significant Leap in Biotech



In a notable market event, Windward Bio Group AG (Nasdaq: WWB), an innovative biotechnology firm, successfully debuted on the Nasdaq Global Select Market on November 13, 2026. Backed by Pivotal bioVenture Partners China, Windward completed its IPO priced at $17 per share and successfully raised approximately $225 million, including a concurrent private placement investment from Sanofi. With an astonishing 68% increase on its first day of trading, the company secured a market capitalization of around $1.69 billion.

Founded in 2024 by the accomplished entrepreneur Dr. Luca Santarelli, Windward Bio operates under a NewCo model, focusing on developing cutting-edge medicines for severe respiratory and dermatologic conditions. Prior to founding Windward, Dr. Santarelli led successful ventures such as VectivBio and Therachon, both of which were acquired. The company has flourished, raising a total of $365 million to date, including a monumental $200 million Series A round in January 2025 and a $165 million crossover financing in May 2026.

Windward's headquarters are strategically located in Basel, Switzerland, from where it spearheads the development of innovative ultra-long-acting antibody therapies. The firm's lead product, WIN378, is a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) and is currently advancing through critical Phase 2/3 trials for asthma and Phase 2 trials for chronic obstructive pulmonary disease (COPD). This groundbreaking therapy promises to significantly reduce the treatment burden for patients, with a unique dosing schedule that allows administration twice yearly, deviating from the conventional four-week cycle.

The momentum didn’t cease with the IPO. Windward recently reported promising interim data supporting the dosing schedule of WIN378 during the ongoing Phase 2 trials in asthma. Furthermore, the company is expanding its portfolio with another promising product, WIN027, a bispecific antibody that is currently in Phase 1 development, targeting both TSLP and interleukin-13 (IL-13).

Interestingly, both WIN378 and WIN027's global rights, excluding certain Asian markets, stem from Chinese biopharmaceutical collaborations. WIN378 emerged from a partnership involving Harbour BioMed and Kelun-Biotech, while WIN027's development includes Qyuns Therapeutics as a key player. This collaboration reflects a growing trend of Chinese biomedical innovations entering global markets through strategic licensing.

Windward exemplifies the NewCo business model, where a global investment firm orchestrates the spin-out of a Chinese company’s assets, forms a new entity abroad, and facilitates international funding and operations for its clinical advancements. Pivotal bioVenture Partners has been a steadfast supporter, participating in each financing phase, ultimately helping propel Windward from a concept to a publicly traded entity in less than two years.

Following the IPO, Windward intends to utilize the net proceeds to enhance its clinical endeavors, particularly by advancing core programs like WIN378 and WIN027. The company aims to reach significant clinical milestones, including top-line data from the WIN378 asthma trials in early 2027 and COPD trial data later that same year. The potential clinical distinction of both WIN378 and WIN027 marks them as leading contenders in treating critical health issues in their respective fields.

Pivotal bioVenture Partners sees Windward as a successful model of their investment philosophy, combining Chinese innovation with global operational expertise. For Windward Bio, this listing not only elevates its profile but also highlights the remarkable journey of Chinese biotech entities adapting successfully to international business landscapes.

Windward Bio’s commitment to innovation and serious disease treatment is set to transform therapeutic landscapes, providing hope and relief to patients worldwide.



About Windward Bio


Windward Bio is on the frontier of biotechnology, committed to redefining treatment approaches for severe immunological conditions. With a seasoned team focusing on long-acting biologics, Windward is paving the way for next-generation therapies.

About Pivotal bioVenture Partners


Founded by Hong Kong's Nan Fung Group and operating since 2017, Pivotal bioVenture Partners specializes in leading advancements in life sciences through extensive international networks and a robust commitment to transformative healthcare.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.